Op Dr Burcu Usta Uslu

10/10/2025

What’s Next for Corneal Cross-Linking via Review of Ophthalmology

Cornea specialists discuss more advanced uses for corneal collagen cross-linking beyond the currently approved treatment protocol in the United States.
https://reviewofophthalmology.com/article/whats-next-for-corneal-crosslinking

10/10/2025

Diagnostic Error High in Corneal Referrals, Study Finds
Ambiguity in terminology and shortcomings in history taking and physical exam all contributed to the presence of such cases sent to an academic tertiary care practice.

The study identified a total of 13 distinct diagnoses that were initially referred in as dry eye disease, some of which were blepharitis, band keratopathy (pictured here), senile furrow degeneration, corneal edema and epiphora.

Read more: https://www.reviewofoptometry.com/article/diagnostic-error-high-in-corneal-referrals-study-finds

08/10/2025

Dry eye is the most common side effect, often resolving in 3–6 months. Remember: Preoperative screening and treatment can optimize patient outcomes. https://ow.ly/MWki50WUSU2

05/10/2025

Kendinizle vakit geçirmek, dinlenmek, keyif yapmak; bunlar da sağlıklı olmanız için gerekli..

İyileşmenin , iyi kalmanın temelinde denge var..

Denge için de çalışmak kadar dinlenmek ve kendini dinlemek de var..

Unutmayınız ..

Saygı & sevgilerimle

İyi pazarlar

21/09/2025

Central Serous Chorioretinopathy Resolves Faster with NSAIDs, Study Finds
Topical treatment resulted in rapid clearance and excellent visual acuity.

The “do nothing and wait” approach is widely used in cases of acute central serous chorioretinopathy (CSCR), which typically resolves on its own within three to six months. But though the condition is self-limited, a significant number of patients still experience recurrence or prolonged duration, which increases the risk for permanent retinal damage and vision loss.

This has inspired investigation of a low-risk high-reward avenue of treatment as an alternative to observation: topical NSAID therapy. “One would not leave cystoid macular edema untreated if a safe treatment exists,” researchers state in a recent Clinical Ophthalmology review paper. They reported more positive evidence supporting this intervention.

Read more in today's News Feed: https://www.reviewofoptometry.com/article/central-serous-chorioretinopathy-resolves-faster-with-nsaids-study-finds

12/09/2025

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

29/08/2025

14/08/2025

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

14/08/2025

Some reassuring news for patients taking GLP-1 receptor agonists: Concerns that the drugs may cause retinopathy may be overblown.
A new analysis of nearly 160,000 people with diabetes taking four different GLP-1 medications for at least a year has found no increased risk for diabetic retinopathy associated with the drugs. http://ms.spr.ly/6180sPI1r